Arena Pharmaceuticals EPS Ratio 2011-2025 | ARNA

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Arena Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-10.1	-7.39	7.99	1.39	-2.77	-0.09	-0.45	-0.28	-0.09	-0.45	-0.8

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
7.99	-10.1	-1.19

Quarterly EPS Ratio Arena Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-3.21	-2.4	-1.98	-2.1	-1.69	-1.61	-2	-1.76	-1.46	-1.24	12.5	1.39	-0.7	-0.65	-0.8	-0.35	-0.86	-0.77	-0.09	1.59	-0.51	-1.12	-0.89	-0.13	-0.11	-0.11	-0.1	-0.15	-0.05	0.03	-0.12	-0.11	-0.08	0.18	-0.09	-0.1	-0.07	-0.12	-0.18	-0.16	-0.16	-0.16	-0.35

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
12.5	-3.21	-0.298

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	-3.87	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	-0.02	$ 223.98	-0.53 %	$ 396 B	USA
Alpine Immune Sciences ALPN	-1.73	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	-0.44	$ 4.67	1.74 %	$ 775 M	Canada
Aclaris Therapeutics ACRS	-1.71	$ 3.36	2.75 %	$ 260 M	USA
AlloVir ALVR	-11.7	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	-0.79	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-0.09	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	-10.7	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	-24.9	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-1.77	-	-0.23 %	$ 916 M	USA
Ascendis Pharma A/S ASND	-8.28	$ 210.16	4.43 %	$ 5 B	Danmark
Ayala Pharmaceuticals AYLA	-2.46	-	-	$ 7.46 M	Israel
Aptorum Group Limited APM	-0.78	$ 1.33	-1.48 %	$ 7.25 M	China
Alterity Therapeutics Limited ATHE	-0.53	$ 3.42	2.09 %	$ 8.23 B	Australia
Amphastar Pharmaceuticals AMPH	3.29	$ 25.9	0.74 %	$ 1.25 B	USA
AstraZeneca PLC AZN	0.08	$ 90.29	-	$ 96.9 B	Britain
Anika Therapeutics ANIK	-5.64	$ 9.49	-	$ 139 M	USA
Brickell Biotech BBI	-1.06	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	-0.47	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	-0.81	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-1.42	-	-7.31 %	$ 87 M	USA
Aytu BioScience AYTU	-2.16	$ 2.28	-	$ 14.3 M	USA
Biogen BIIB	11.2	$ 172.5	-	$ 25.1 B	USA
Baudax Bio BXRX	-177	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	-15.8	-	-52.27 %	$ 4.45 M	USA
Benitec Biopharma BNTC	-0.21	$ 12.96	1.17 %	$ 533 M	USA
ChromaDex Corporation CDXC	0.11	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	4.98	$ 581.03	2.22 %	$ 44 B	USA
Can-Fite BioPharma Ltd. CANF	-0.01	$ 0.29	-0.31 %	$ 631 M	Israel
Checkpoint Therapeutics CKPT	-1.42	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-2.4	-	-16.75 %	$ 25.8 M	USA
Catalyst Biosciences CBIO	-1.41	$ 15.31	-	$ 1.01 B	USA
Clovis Oncology CLVS	-2.29	-	-7.23 %	$ 13 M	USA
Cerus Corporation CERS	-0.11	$ 2.15	13.76 %	$ 397 M	USA
BioVie BIVI	-12.1	$ 1.51	-4.43 %	$ 2.23 M	USA
Cortexyme CRTX	-0.84	-	-1.05 %	$ 67.1 M	USA
Celldex Therapeutics CLDX	-2.45	$ 27.94	-	$ 1.8 M	USA
Cellectar Biosciences CLRB	-3.5	$ 3.78	-5.97 %	$ 46.2 M	USA
Deciphera Pharmaceuticals DCPH	-2.29	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-13.1	$ 11.44	7.92 %	$ 740 M	USA
BioNTech SE BNTX	42.2	$ 96.0	-	$ 27.2 B	Germany
Eloxx Pharmaceuticals ELOX	-16.6	-	-5.68 %	$ 8.28 M	USA
Acer Therapeutics ACER	-1.66	-	2.71 %	$ 14 M	USA
Enochian Biosciences ENOB	-1.08	-	-	$ 40.5 M	USA
Epizyme EPZM	-2.45	-	-	$ 249 M	USA